Liver volume: the point of no return in liver transplantation?

Abstract

for malignancies 2 or small -for -size syndrome in the recipients of living -donor grafts. 3 However, a smaller liver volume (LV) is observed in advanced liver cirrhosis with an increasing Child-Pugh class (CPC). 1,4-6 Additionally, according to Ozaki et al, 1 morphometric differences between etiologies would decrease with progression of cirrhosis. In individuals with cirrhosis and portal hypertension, only a 75% LV is expected compared with age -matched controls. 7 Changes in LV over time were suggested to be an indicator of therapeutic effectiveness or liver disease progression. 8 The advent of novel direct antiviral agents (DAAs), with a 90% efficacy of sustained viral IntroductIon Liver cirrhosis is characterized by several alterations affecting the hepatic tissue: fibrotic deposits involving the centrilobular vein, perisinusoidal space, and portal triad; active hepatocellular hyperplasia; and nodular formation with disruption of the normal microvascular architecture of the hepatic sinusoids, leading to progressive derangement of the liver morphology and function. However, Ozaki et al 1 noted numerous morphometric changes in liver modeling across various etiologies of cirrhosis.Liver volumetry is a method used to assess the risk of inducing liver failure in candidates for liver resection prior to hepatectomy

Metodologías de Medición de Volumetría Hepática

“…Otro grupo de pacientes en quienes es especialmente relevante la correcta medición del VHT es en aquellos que serán sometidos a trasplante hepático, tanto para los donantes como los receptores cuando el trasplante proviene de donante vivo, ya que de no ser realizada correctamente, puede derivar en insuficiencia hepática post hepatectomía y en el síndrome pequeño para el tamaño o "small for size" (Nakayama et al, 2006;Miarka et al, 2020).…”

Sarcopenia and cachexia in chronic diseases: from mechanisms to treatment

“…Since there is no agreement upon a standard definition for either disorder, it is difficult to make comparisons between studies. Sarcopenia and cachexia can complicate many different chronic diseases including cancer6, heart failure (HF) [7,8], chronic kidney disease (CKD) [9,10], thyroid disease [11], chronic obstructive pulmonary disease (COPD) [12], and chronic liver failure [13]. Once wasting disorders occur they can aggravate the clinical condition of patients, impair their quality of life, cause prolonged or repeated hospitalizations, and potentially worsen patient prognoses [14].…”